Brief: Everest Medicines Announces Data From Phase I Study Of Ever206
17/01/2023 23:31
Jan 17 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES TOP-LINE DATA FROM PHASE I
STUDY OF
EVER206 ON HEALTHY SUBJECTS IN CHINA
* EVEREST MEDICINES LTD - STUDY FINDINGS SUGGEST THAT
EVER206 IS
WELL-TOLERATED WITH NO NEW SAFETY SIGNALS
Source text for Eikon: ID:nPnbgn2Fza
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region